NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2022, Vol. 34 ›› Issue (6): 1014-1020. doi: 10.16333/j.1001-6880.2022.6.014

Previous Articles     Next Articles

Nodakenin exerts anti-hepatocellular carcinoma effects by regulating CXCL5-ERK/MEK signal axis

WANG Peng-li,WANG Guo-tai,YAN Shu-guang,LI Jing-tao,LUO Lu,BAI Yao,ZHOU Xiao-yan*   

  1. Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang 712000,China
  • Online:2022-06-28 Published:2022-06-30

Abstract:

This paper investigates the effect and mechanism of nodakenin (NK) on hepatocellular carcinoma cells.HepG2 and MHCC-97H cells were treated with different concentrations of NK.Cell proliferations were detected by CCK-8,and migration and invasion abilities were observed by cell scratch and Trans-wells experiments.NK significantly inhibited the proliferation,migration and invasion of HepG2 and MHCC-97H cells in vitro.RNA-seq was conducted to analyze the expression of each gene before and after the administration of NK.qRT-PCR,Western blotting and cellular immunofluorescence were used to verify the RNA-seq result.The results showed that the expression of chemokine 5 (CXCL5) was significantly decreased after administration of NK,and the phosphorylation of ERK and MEK was inhibited at the same time.In summary,it can be concluded that NK inhibits ERK/MEK signaling pathway by down-regulating CXCL5,thereby inhibiting hepatocellular carcinoma.

Key words: nodakenin, CXCL5, ERK/MEK, liver cancer

CLC Number: